ONC•businesswire•
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies
Summary
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on December 7, 2025 by businesswire